课题基金 / 基金详情

项目摘要

项目成果

ROBERT A SEDER的其他基金

相似基金

相关文献

中文摘要
翻译
今年的主要发现如下。 1.启动了一项I期临床试验,评估IV或IM途径给予的辐照PfSPZ是否安全,并使用各种剂量和免疫间隔给予持久的免疫力和保护。 2.表征了接种疫苗和感染后子孢子特异性T细胞和NK反应的纵向特征,以提供对保护相关性的见解。使用Fluidigm表征接种疫苗/受保护与接种疫苗/未受保护或对照感染受试者中子孢子特异性CD 4 + T细胞应答的异质性。 3.在接种疫苗和受保护受试者中分离抗疟疾特异性蛋白(例如CSP)的单克隆抗体。
英文摘要
The major discovery this year are as follows. 1. Initiated a phase I clinical trial assessing whether irradiated PfSPZ given by the IV or IM route is safe, and confers durable immunity and protection using various doses and intervals for immunization. 2. Characterized the sporozoite specific T cell and NK responses longitudinally following vaccination and infection to provide insights into the correlates of protection. Used Fluidigm to characterize the heterogeneity of the sporozoite specific CD4+ T cell response in vaccinated/protected versus vaccinated/unprotected or control infected subjects. 3. Isolated monoclonal antibodies against malaria specific proteins ( eg CSP) in vaccinated and protected subjects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VACCINE DEVELOPMENT FOR TUBERCULOSIS
  • 批准号:
    7958684
  • 项目类别:
  • 资助金额:
    $5.57万
  • 财政年份:
    2009
  • 负责人:
    ROBERT A SEDER
  • 依托单位:
DNA VACCINATION FOR PREVENTION OF VIRAL, PARASITIC AND MYCOBACTERIAL INFECTION
Development Of A Vaccine For Leishmania Major Infection
Development Of A Vaccine For Leishmania Major Infection
海外基金